Surge in prevalence of chronic disorders, rise in R&D activities, and increase in industry-academia collaborations are prominently driving the mRNA vaccines and therapeutics market revenue.
The field of vaccination has undergone a revolution owing to the development of mRNA-based vaccines, which has also fueled the market for messenger RNA vaccines.
Leading companies in mRNA vaccine development are offering a wide spectrum of drug classes and platform technologies, including mRNA-based therapeutics, that have the potential to be combined with each other or with approved therapies in a synergistic manner.
In line with the latest mRNA vaccines and therapeutics market trends, key players are engaged in innovations in mRNA vaccine technology in order to expand the applications of mRNA therapeutics.
Messenger Ribonucleic Acid (mRNA) is a single protein-coding gene in the genome that acts as a basis for protein synthesis within the cells. mRNA vaccines and therapeutics are developed in labs employing a variety of mammalian cells and combine necessary immunological characteristics.
Some of the frequently used vaccine and therapeutics are usually self-amplifying, non-replicating, in vivo self-replicating, and in vitro dendritic cell non-replicating mRNA.
Injecting them into the body causes the production of viral antigen proteins within the cells and activates immunological sensors that recognize viruses. This enhances B- and T-cell responses, which helps strengthen the body's immunity.
| Attribute | Detail |
|---|---|
| mRNA Vaccines and Therapeutics Market Drivers |
|
Chronic diseases are long-term illnesses that can often be incurable. Increase in tobacco consumption, adoption of poor diet, lack of physical activities, and excessive consumption of alcohol are key factors that impose a substantial health burden globally, thereby prompting the need for more effective treatment options.
According to the National Institutes for Health (NIH), the number of people suffering from chronic diseases is expected to rise steadily in the next 30 years.
As per the National Center for Biotechnology Information (NCBI), of the population 50 years and older in the U.S., the number of people afflicted with chronic diseases is likely to surge by 99.5%, rising from around 71 million in 2020 to approximately 142 million by the year 2050.
mRNA-based therapeutics offer versatility. They can treat diseases requiring protein expression more effectively than transient protein-based drugs. mRNA’s continuous translation into proteins ensures long-lasting expression, benefiting patients with incurable conditions.
mRNA can instruct cells to produce proteins, potentially offering targeted therapies and vaccines tailored to individual genetic profiles.
Thus, increase in demand for effective treatments and vaccines that are capable of addressing complex health challenges is fueling the mRNA vaccines and therapeutics market size.
Companies operating in the global mRNA vaccines and therapeutics industry are making efforts to enhance lipid nanoparticle formulations for in-vivo systemic delivery of mRNA.
They are collaborating with leading nucleic acid delivery companies that offer excellent platforms to develop novel vaccines and therapeutics that could help physicians treat cancer subtypes, rare life-threatening diseases, and pursue new and better approaches to combat other infectious diseases.
In August 2023, Gritstone bio, Inc., a clinical-stage biotechnology company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, entered into an agreement.
As per the agreement, Gritstone bio, Inc. will have a multi-year option for a non-exclusive license under Genevant’s LNP technology on a pathogen-by-pathogen basis to develop and commercialize self-amplifying RNA (samRNA) vaccines.
In January 2023, Arcturus Therapeutics Holdings Inc. announced that the Clinical Trial Application (CTA) for ARCT-032, an inhaled investigational mRNA medicine to treat cystic fibrosis (CF), received approval to proceed into a Phase 1 First-in-Human study in New Zealand.
Thus, rise in R&D activities and industry-academia partnerships are fueling market expansion.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest mRNA vaccines and therapeutics market analysis, North America constituted the leading share of the global landscape in 2023.
Increase in research and development activities and growth in regulatory approvals for mRNA vaccines such as those for Pfizer-BioNTech and Moderna are fostering mRNA vaccines and therapeutics market development in North America.
Rise in number of government-led vaccination campaign centers and presence of established and emerging pharmaceutical companies are also boosting the mRNA vaccines and therapeutics market share of the region.
Companies operating in the global mRNA vaccines and therapeutics market are investing substantially in R&D activities to introduce advanced mRNA vaccine technology in order to expand the application of mRNA beyond infectious diseases.
Observing the latest market trends in mRNA vaccines and therapeutics, prominent players are engaged in new class of mRNA drug development to bring about a sustainable change in biomedical research.
Moderna, Inc., BioNTech SE., CureVac SE, Arcturus Therapeutics, Inc., Sanofi, GSK plc, Argos Therapeutics Inc., Ethris, Pfizer Inc., and AstraZeneca are the prominent companies functioning in the global mRNA vaccines and therapeutics landscape.
These companies have been profiled in the mRNA vaccines and therapeutics market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 19.6 Bn |
| Market Forecast (Value) in 2034 | US$ 85.9 Bn |
| Growth Rate (CAGR) | 14.6% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 19.6 Bn in 2023
It is projected to advance at a CAGR of 14.6% from 2024 to 2034
Increase in prevalence of chronic diseases, and growth in R&D activities and industry-academia collaborations
North America was the dominant region in 2023
Moderna, Inc., BioNTech SE, CureVac SE, Arcturus Therapeutics, Inc., Sanofi, GSK plc, Argos Therapeutics Inc., Ethris, Pfizer Inc., and AstraZeneca
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global mRNA Vaccines and Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by mRNA Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by mRNA Type, 2020-2034
6.3.1. Nucleoside-modified mRNA
6.3.2. Unmodified mRNA
6.3.3. Self-amplifying mRNA
6.4. Market Attractiveness, by mRNA Type
7. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type, 2020-2034
7.3.1. Prophylactic
7.3.2. Therapeutic
7.3.3. 7.4 Market Attractiveness, by Type
8. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2020-2034
8.3.1. Infectious Diseases
8.3.2. Oncology
8.3.3. Rare Genetic Diseases
8.3.4. Others (Respiratory Diseases, etc.)
8.4. Market Attractiveness, by Application
9. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals & Clinics
9.3.2. Biopharmaceutical Companies
9.3.3. Others (Research Organizations, etc.)
9.4. Market Attractiveness, by End-user
10. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America mRNA Vaccines and Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by mRNA Type, 2020-2034
11.2.1. Nucleoside-modified mRNA
11.2.2. Unmodified mRNA
11.2.3. Self-amplifying mRNA
11.3. Market Attractiveness, by mRNA Type
11.4. Market Value Forecast, by Type, 2020-2034
11.4.1. Prophylactic
11.4.2. Therapeutic
11.5. Market Attractiveness, by Type
11.6. Market Value Forecast, by Application, 2020-2034
11.6.1. Infectious Diseases
11.6.2. Oncology
11.6.3. Rare Genetic Diseases
11.6.4. Others (Respiratory Diseases, etc.)
11.7. Market Attractiveness, by Application
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals & Clinics
11.8.2. Biopharmaceutical Companies
11.8.3. Others (Research Organizations, etc.)
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By mRNA Type
11.11.2. By Type
11.11.3. By Application
11.11.4. By End-user
11.11.5. By Country
12. Europe mRNA Vaccines and Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by mRNA Type, 2020-2034
12.2.1. Nucleoside-modified mRNA
12.2.2. Unmodified mRNA
12.2.3. Self-amplifying mRNA
12.3. Market Attractiveness, by mRNA Type
12.4. Market Value Forecast, by Type, 2020-2034
12.4.1. Prophylactic
12.4.2. Therapeutic
12.5. Market Attractiveness, by Type
12.6. Market Value Forecast, by Application, 2020-2034
12.6.1. Infectious Diseases
12.6.2. Oncology
12.6.3. Rare Genetic Diseases
12.6.4. Others (Respiratory Diseases, etc.)
12.7. Market Attractiveness, by Application
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals & Clinics
12.8.2. Biopharmaceutical Companies
12.8.3. Others (Research Organizations, etc.)
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By mRNA Type
12.11.2. By Type
12.11.3. By Application
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific mRNA Vaccines and Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by mRNA Type, 2020-2034
13.2.1. Nucleoside-modified mRNA
13.2.2. Unmodified mRNA
13.2.3. Self-amplifying mRNA
13.3. Market Attractiveness, by mRNA Type
13.4. Market Value Forecast, by Type, 2020-2034
13.4.1. Prophylactic
13.4.2. Therapeutic
13.5. Market Attractiveness, by Type
13.6. Market Value Forecast, by Application, 2020-2034
13.6.1. Infectious Diseases
13.6.2. Oncology
13.6.3. Rare Genetic Diseases
13.6.4. Others (Respiratory Diseases, etc.)
13.7. Market Attractiveness, by Application
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals & Clinics
13.8.2. Biopharmaceutical Companies
13.8.3. Others (Research Organizations, etc.)
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By mRNA Type
13.11.2. By Type
13.11.3. By Application
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America mRNA Vaccines and Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by mRNA Type, 2020-2034
14.2.1. Nucleoside-modified mRNA
14.2.2. Unmodified mRNA
14.2.3. Self-amplifying mRNA
14.3. Market Attractiveness, by mRNA Type
14.4. Market Value Forecast, by Type, 2020-2034
14.4.1. Prophylactic
14.4.2. Therapeutic
14.5. Market Attractiveness, by Type
14.6. Market Value Forecast, by Application, 2020-2034
14.6.1. Infectious Diseases
14.6.2. Oncology
14.6.3. Rare Genetic Diseases
14.6.4. Others (Respiratory Diseases, etc.)
14.7. Market Attractiveness, by Application
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals & Clinics
14.8.2. Biopharmaceutical Companies
14.8.3. Others (Research Organizations, etc.)
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By mRNA Type
14.11.2. By Type
14.11.3. By Application
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa mRNA Vaccines and Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by mRNA Type, 2020-2034
15.2.1. Nucleoside-modified mRNA
15.2.2. Unmodified mRNA
15.2.3. Self-amplifying mRNA
15.3. Market Attractiveness, by mRNA Type
15.4. Market Value Forecast, by Type, 2020-2034
15.4.1. Prophylactic
15.4.2. Therapeutic
15.5. Market Attractiveness, by Type
15.6. Market Value Forecast, by Application, 2020-2034
15.6.1. Infectious Diseases
15.6.2. Oncology
15.6.3. Rare Genetic Diseases
15.6.4. Others (Respiratory Diseases, etc.)
15.7. Market Attractiveness, by Application
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals & Clinics
15.8.2. Biopharmaceutical Companies
15.8.3. Others (Research Organizations, etc.)
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By mRNA Type
15.11.2. By Type
15.11.3. By Application
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Moderna, Inc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. BioNTech SE.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. CureVac SE
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Arcturus Therapeutics, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Sanofi
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. GSK plc
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Argos Therapeutics Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Ethris
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Pfizer Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. AstraZeneca
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034
Table 02: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 03: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 05: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 06: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 07: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034
Table 08: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 09: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 10: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 11: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034
Table 13: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 14: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 15: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034
Table 18: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 19: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 20: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034
Table 23: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 24: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 25: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 26: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034
Table 28: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034
Table 29: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 30: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn), by Region, 2023 and 2034
Figure 02: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by mRNA Type, 2023
Figure 03: Global mRNA Vaccines and Therapeutics Market Value Share, by mRNA Type, 2023
Figure 04: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by Type, 2023
Figure 05: Global mRNA Vaccines and Therapeutics Market Value Share, by Type, 2023
Figure 06: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by Application, 2023
Figure 07: Global mRNA Vaccines and Therapeutics Market Value Share, by Application, 2023
Figure 08: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by End-user, 2023
Figure 09: Global mRNA Vaccines and Therapeutics Market Value Share, by End-user, 2023
Figure 10: Global mRNA Vaccines and Therapeutics Market Value Share, by Region, 2023
Figure 11: Global mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast, 2020-2034
Figure 12: Global mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034
Figure 13: Global mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034
Figure 14: Global mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034
Figure 15: Global mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034
Figure 16: Global mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034
Figure 17: Global mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034
Figure 18: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by End-user, 2023
Figure 19: Global mRNA Vaccines and Therapeutics Market Value Share, by End-user, 2023
Figure 20: Global mRNA Vaccines and Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034
Figure 26: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034
Figure 27: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034
Figure 28: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 29: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034
Figure 30: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034
Figure 31: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034
Figure 32: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034
Figure 37: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034
Figure 38: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034
Figure 39: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034
Figure 41: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034
Figure 42: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034
Figure 43: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034
Figure 48: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034
Figure 49: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034
Figure 50: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034
Figure 52: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034
Figure 53: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034
Figure 54: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 55: Latin America mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034
Figure 59: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034
Figure 60: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034
Figure 61: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 62: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034
Figure 63: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034
Figure 64: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034
Figure 65: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034
Figure 70: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034
Figure 71: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034
Figure 72: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 73: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034
Figure 74: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034
Figure 75: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034
Figure 76: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
mRNA Vaccines and Therapeutics Market
